However, resistance to ICI therapies is relatively common, with 55% of melanoma patients presenting innate resistance to anti-PD-1; 40% to anti-PD-1/anti-CTLA-4 combination; and 25% patients developing resistance to anti-PD-1 within two years of treatment [2]. This evidence concerns the gene PDCD1 and melanoma.